Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Disaggregated base case results including cost components and incremental results

From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

Conventional care failure population
  Cost components (€)
Drug costs (€) Administration costs Health state costs Indirect costs Adverse event cost
Ustekinumab 50,352 312 55,127 111,987 14,447
Adalimumab 41,942 996 57,767 118,962 19,543
  Total and incremental results
Cost (€) Incremental cost QALYs Incremental QALYs ICER (€)
Ustekinumab 232,225   14.275   
Adalimumab 239,209 6984 14.043 − 0.232 Dominated
TNF-alpha failure population
  Cost components (€)
Drug costs (€) Administration costs Health state costs Indirect costs Adverse event cost
Vedolizumab 31,885 2293 62,767 132,895 14,881
Ustekinumab 43,501 336 61,206 128,843 14,859
  Total and incremental results
Total cost (€) Incremental cost Total QALYs Incremental QALYs ICER (€)
Vedolizumab 244,721   14.047   
Ustekinumab 248,745 4023 14.180 0.133 30,282
  1. QALY quality adjusted life year, ICER incremental cost-effectiveness ratio, TNF tumour necrosis factor